Gilead Sciences is investing $250m in LEO Pharma’s preclinical small molecules. According to the deal, Gilead will develop oral versions of the potential inflammation drugs, while Denmark’s LEO will focus on topical versions. Additional payments of up to $1.7bn could go to LEO, depending on the research’s progress. The molecules are being developed to target IL-4 and IL-13 proteins, known to be linked to inflammation.
Free VPN risk: Check this list of 9 infected apps
The use of free Virtual Private Networks (VPNs) can compromise your online privacy and security. Data suggests about 80% of free VPNs have tracking features,
